FB23-2
FB23-2 Basic information
- Product Name:
- FB23-2
- Synonyms:
-
- FB23-2
- FB23-2(FTO Demethylase inhibitor FB23-2)
- Benzamide, 2-[[2,6-dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxy-
- FB23-2，1.5g
- 2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxybenzamide
- FB23 2,AML,Apoptosis,leukemia,acute,anti-proliferation,Inhibitor,FB232,m6A,myeloid,mRNA,inhibit,FB23-2,demethylase,FB-23-2
- 2-((2,6-Dichloro-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)-N-hydroxybenzamide
- FB23-2, 10 mM in DMSO
- CAS:
- 2243736-45-8
- MF:
- C18H15Cl2N3O3
- MW:
- 392.24
- Mol File:
- 2243736-45-8.mol
More
Less
FB23-2 Chemical Properties
- Density
- 1.428±0.06 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- DMSO:70.25(Max Conc. mg/mL);179.1(Max Conc. mM)
- form
- A solid
- pka
- 8.72±0.40(Predicted)
- color
- White to light yellow
More
Less
FB23-2 Usage And Synthesis
Uses
FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML)[1].
in vivo
FB23-2 (2 mg/kg; i.p.; daily; for 10 days) substantially suppresses leukemia progression and prolongs survival[1].
FB23-2 exhibits elimination half-life (rat 6.7 h) and Cmax (rat 2421.3 ng/mL) following intraperitoneal injection (rat 3 mg/kg)[1].
| Animal Model: | NOD/LtSz-scid IL2RG-SGM3 (NSGS) mice, xeno-transplanted with MONOMAC6 AML cells[1] |
| Dosage: | 2 mg/kg |
| Administration: | Intraperitoneal injection, daily, for 10 days |
| Result: | Delayed the onset of full-blown leukemic symptoms and significantly prolonged survival by almost doubling the median survival. |
| Animal Model: | Sprague Dawley (SD) rats[1] |
| Dosage: | 3 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Intraperitoneal injection |
| Result: | T1/2 (6.7 hours), Cmax (2421.3 ng/mL). |
References
[1] Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. DOI:10.1016/j.ccell.2019.03.006
FB23-2Supplier
ShangHai Caerulum Pharma Discovery Co., Ltd.
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
Mashilabs (Shanghai) Co.,Ltd.
- Tel
- 19916721580
- mafarm@126.com
Shanghai Xingui Biotechnology Co., Ltd.
- Tel
- 15121041756
- xingui2022@126.com
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com